Filter by Year: ALL 2022 2021 2020 2019 2018 2017 2015 Source Endpoints Eli Lilly's Van Naarden hands $380M cash to Flagship-backed upstart in major new oncology deal December 13, 2021 Source Bloomberg Lilly Joins Foghorn in $380 Million Pact for Genetic Cancer Treatments December 13, 2021 Source MedCityNews Eli Lilly steers into Foghorn’s gene traffic control drugs with $380M pact in cancer December 13, 2021 Source FierceBiotech Eli Lilly puts $1.3B in biobucks on the line for Foghorn's oncology programs December 13, 2021 Source Targeted Oncology Treatment With FHD-609 Begins in Phase 1 Synovial Sarcoma Study August 23, 2021 Source PharmaVoice CMO Sam Agresta Named to PharmaVOICE 100 August 1, 2021 Source BioSpace Q&A: Foghorn SVP Expounds on "Tremendous Opportunity" in Chromatin Remodeling April 20, 2021